Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
about
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens.The developing story of Sprouty and cancer.Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformationSprouty 1 predicts prognosis in human epithelial ovarian cancerRole of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells.Kif3a is necessary for initiation and maintenance of medulloblastoma.Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma via c-myc-dependent and -independent events.Caveolins in rhabdomyosarcomaProof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility.Sprouty2 but not Sprouty4 is a potent inhibitor of cell proliferation and migration of osteosarcoma cells.In non-small cell lung cancer mitogenic signaling leaves Sprouty1 protein levels unaffected.Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathwayHuman sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion.Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.Sprouty4 mRNA variants and protein expressions in breast and lung-derived cells.A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogen-mediated changes in cell cycle regulatory circuits.Differential expression of sprouty genes in hepatocellular carcinoma.High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis.Meta-Analysis and Experimental Validation Identified FREM2 and SPRY1 as New Glioblastoma Marker Candidates.
P2860
Q30418118-D675FF82-A282-4A07-985C-BC139F741F49Q33750182-B19F721C-DEC2-444F-8A94-F876C3776463Q33798340-D5C4C8E7-A1F3-46B6-B70F-8183CE6C80CFQ33962853-9E4E7BBB-976F-4D26-A41C-8FD159E503CEQ34613149-E6FC513F-A0FD-44E2-9158-9CF2D4964997Q35758025-9F8ED1D7-5867-476C-9CA5-B2C24400FB27Q35819280-5F895C22-5E08-4061-A4BA-1ABAFA9E4C7CQ36142754-75F06D58-C2EC-4559-9BB3-4DFE716D3F3AQ36599973-24639742-DE1B-4A5B-A7C4-6033F6D2D36EQ36686648-75FF0E67-5302-4645-AE3F-5B1492273BDDQ36895049-9D16C73C-E6ED-4CE6-8AC5-ABD5721DD4FAQ36895367-73B3FFFC-9246-41AC-AB23-D420523C0041Q37464647-B9120D5A-B4DE-41F3-B1C2-6D3F050544AAQ37648694-1E7B6317-020E-4DDC-B2F2-36A1BF30A97AQ37894860-2186FEDF-5925-4697-B16F-C37DCAE4B502Q38105879-7418372A-4EA8-4A16-AA9B-CA40D212BAD9Q38261355-8E4E2F39-EB2B-4C5D-9D01-C41BE1F52D1BQ39129630-85DC868A-ACAE-47F5-AED4-879B9F4E6183Q39160896-08732A7B-D40F-42A0-AF23-8C7C9CA0F78DQ39174563-0072BB5E-0D00-4D37-AD33-A93FBDBAC786Q39502584-9E60FC55-F6B6-46D4-BE45-ABCF24FC4FF3Q41513194-F1B67DCA-D6F7-4C60-AEED-80E29E2F97EAQ42137707-1D6A205F-7261-449B-8357-28626DD09B90Q47782462-BC247BC5-D747-44ED-837B-A82AEAE72235Q48360902-5764ECF1-7F3F-434F-BA6B-958D3F1C786BQ54348091-DAC3508F-03B3-4862-8F1F-3257B874A76FQ54603571-8855E013-C201-460C-BED7-887C5EAA9D46Q55361003-634F0225-9E5A-4BF7-B8C5-5D3C2EF932FC
P2860
Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@ast
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@en
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@nl
type
label
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@ast
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@en
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@nl
prefLabel
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@ast
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@en
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@nl
P2093
P50
P1433
P1476
Silencing of SPRY1 triggers co ...... s carrying a mutated RAS gene.
@en
P2093
Arjan Lakeman
Danny Zwijnenburg
Marcel Kool
Mohamed Hamdi
P304
P356
10.1158/0008-5472.CAN-09-2532
P407
P577
2010-01-12T00:00:00Z